Vesicocutaneous fistula formation during treatment with sunitinib malate: Case report

BMC Gastroenterology

Volumn 10, Issue , 2010, Pages

  Watanabe, Koichiro ^a   Otsu, Satoshi ^a   Morinaga, Ryotaro ^a   Kawano, Sakura ^a   Hirashima, Yoshinori ^a   Sakashita, Hiroyuki ^b   Shirao, Kuniaki ^a  

^a OITA UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IMATINIB; INDIGO CARMINE; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ABDOMINAL WALL; ADULT; ARTICLE; BLADDER WALL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FEVER; DRUG WITHDRAWAL; ENTEROCUTANEOUS FISTULA; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEMATURIA; HEMICOLECTOMY; HUMAN; HYPOTHYROIDISM; IMAGE ANALYSIS; LEUKOCYTOSIS; LEUKOPENIA; MESENTERY TUMOR; MICTURITION DISORDER; NAUSEA; PARTIAL HEPATECTOMY; PATIENT REFERRAL; PELVIS TUMOR; PERITONEUM TUMOR; SIDE EFFECT; SKIN FISTULA; TUMOR VOLUME; VOMITING; CHEMICALLY INDUCED DISORDER; FOLLOW UP; INTRAARTERIAL DRUG ADMINISTRATION; MIDDLE AGED; URINARY TRACT FISTULA;

ANTINEOPLASTIC AGENTS; CUTANEOUS FISTULA; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; INFUSIONS, INTRA-ARTERIAL; MIDDLE AGED; PYRROLES; TOMOGRAPHY, X-RAY COMPUTED; URINARY FISTULA;

EID: 77958614758     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-10-128     Document Type: Article

References (10)

1. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24(1):25-35. 10.1200/JCO.2005.02.2194, 16314617.
2. Nishida T, Takahashi T, Nishitani A, Doi T, Shirao K, Komatsu Y, Nakajima K, Hirota S. Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. Int J Clin Oncol 2009, 14:143-149. 10.1007/s10147-008-0822-y, 19390946.
3. Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, Li Y, Ueda E, Ohtsu A. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs 2009, 28(6):866-75.
4. Quek R, George S. Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib. Biologics 2010, 4:19-31. 2819895, 20161982.
5. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007, 6:734-745. 10.1038/nrd2380, 17690708.
6. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368(9544):1329-1338. 10.1016/S0140-6736(06)69446-4, 17046465.
7. Judson I. Gastrointestinal stromal tumours (GIST): biology and treatment. Ann Oncol 2002, 13(Suppl 4):287-289.
8. Mackay HJ, Tinker A, Winquist E, Thomas G, Swenerton K, Oza A, Sederias J, Ivy P, Eisenhauer EA. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 2010, 116:163-167. 10.1016/j.ygyno.2009.08.012, 19740535.
9. Ng EK, Wong SK, Mok TS, Chan WY, Chung SC. Imatinib (STI-571) heals a gastrocutaneous fistula resulting from a malignant gastric stromal tumor. Gastric Cancer 2003, 6:122-126.
10. Ghanem N, Altehoefer C, Furtwangler A, Winterer J, Schafer O, Springer O, Kotter E, Langer M. Computed tomography in gastrointestinal stromal tumors. Eur Radiol 2003, 13:1669-1678. 10.1007/s00330-002-1803-6, 12835984.